385 related articles for article (PubMed ID: 1726206)
41. [Clinical evaluation of cefpodoxime proxetil on the treatment of bacterial infections].
Li JT; Hou J; Kao L
Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):440-3. PubMed ID: 7867436
[TBL] [Abstract][Full Text] [Related]
42. [Clinical evaluation of a new oral cephem, cefpodoxime proxetil in children].
Meguro H; Arimasu O; Shiraishi H; Tajima T; Hiruma F; Nishimura S; Sugie N; Sugamata K; Abe T; Fujii R
Jpn J Antibiot; 1989 Jul; 42(7):1561-70. PubMed ID: 2810730
[TBL] [Abstract][Full Text] [Related]
43. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Bryson HM; Brogden RN
Drugs; 1993 Apr; 45(4):589-621. PubMed ID: 7684677
[TBL] [Abstract][Full Text] [Related]
44. [Pharmacokinetic and clinical studies on cefpodoxime proxetil dry syrup in the field of pediatrics].
Motohiro T; Oda K; Aramaki M; Kawakami A; Tanaka K; Koga T; Sakata Y; Fujimoto T; Yokochi K; Yamashita F
Jpn J Antibiot; 1989 Jul; 42(7):1629-66. PubMed ID: 2681864
[TBL] [Abstract][Full Text] [Related]
45. Cost saving of 5-day therapy with cefpodoxime proxetil versus standard 10-day beta-lactam therapy for recurrent pharyngotonsillitis in adults. A prospective general practice study.
Pelc A; Portier H; Gehanno P; Fiessinger S; Ichou F
Pharmacoeconomics; 1996 Sep; 10(3):239-50. PubMed ID: 10172792
[TBL] [Abstract][Full Text] [Related]
46. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
Melo-Cristino J; Fernandes ML; Serrano N;
Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
[TBL] [Abstract][Full Text] [Related]
47. Acute bacterial rhinosinusitis in pediatric medicine: current issues in diagnosis and management.
Anon JB
Paediatr Drugs; 2003; 5 Suppl 1():25-33. PubMed ID: 14632103
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.
Sarubbi FA; Verghese A; Caggiano C; Holtsclaw-Berk S; Berk SL
Antimicrob Agents Chemother; 1989 Jan; 33(1):113-4. PubMed ID: 2496654
[TBL] [Abstract][Full Text] [Related]
49. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
Pal RB; Pal P; Jain S; Kulkarni KP
J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
[TBL] [Abstract][Full Text] [Related]
50. Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media.
Mendelman PM; Del Beccaro MA; McLinn SE; Todd WM
J Pediatr; 1992 Sep; 121(3):459-65. PubMed ID: 1517926
[TBL] [Abstract][Full Text] [Related]
51. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study.
van Zyl L; le Roux JG; LaFata JA; Volk RS; Palo WA; Flamm R; Hom RC
Clin Ther; 2002 Nov; 24(11):1840-53. PubMed ID: 12501878
[TBL] [Abstract][Full Text] [Related]
52. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
Barberán J; Mensa J
Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
[TBL] [Abstract][Full Text] [Related]
53. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
[TBL] [Abstract][Full Text] [Related]
54. [Clinical studies of cefpodoxime proxetil in respiratory tract infections].
Odagiri S; Matsunaga K; Suzuki K; Murohashi K; Takahashi H; Numata H; Takahashi K; Yamaki I; Ishii S
Jpn J Antibiot; 1988 Oct; 41(10):1538-44. PubMed ID: 3204658
[TBL] [Abstract][Full Text] [Related]
55. Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis.
Gehanno P; Depondt J; Barry B; Simonet M; Dewever H
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():87-91. PubMed ID: 2127269
[TBL] [Abstract][Full Text] [Related]
56. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies.
Baldwin DR; Wise R; Andrews JM; Honeybourne D
J Antimicrob Chemother; 1992 Jul; 30(1):67-71. PubMed ID: 1429338
[TBL] [Abstract][Full Text] [Related]
57. Basing empiric treatment choices for respiratory tract infection on the results of the Alexander Project.
Garau J
J Chemother; 1999 Feb; 11 Suppl 1():51-5. PubMed ID: 10207774
[TBL] [Abstract][Full Text] [Related]
58. Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study.
Thornsberry C; Sahm DF
Chemotherapy; 2000; 46 Suppl 1():15-23. PubMed ID: 10810209
[TBL] [Abstract][Full Text] [Related]
59. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.
Pichichero ME; Doern GV; Kuti JL; Nicolau DP
Paediatr Drugs; 2008; 10(6):391-7. PubMed ID: 18998749
[TBL] [Abstract][Full Text] [Related]
60. Cefpodoxime: pharmacokinetics and therapeutic uses.
Chugh K; Agrawal S
Indian J Pediatr; 2003 Mar; 70(3):227-31. PubMed ID: 12785294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
